이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

SQI Diagnostics 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Andrew Morris

최고 경영자

CA$543.0k

총 보상

CEO 급여 비율	73.7%
CEO 임기	2yrs
CEO 소유권	0.09%
경영진 평균 재임 기간	3.5yrs
이사회 평균 재임 기간	8.4yrs

최근 관리 업데이트

Recent updates

If You Had Bought SQI Diagnostics (CVE:SQD) Stock A Year Ago, You Could Pocket A 246% Gain Today

Dec 22

Is SQI Diagnostics (CVE:SQD) Using Debt Sensibly?

Nov 17

CEO 보상 분석

Andrew Morris 의 보수는 SQI Diagnostics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2023	n/a	n/a	-CA$19m
Dec 31 2022	n/a	n/a	-CA$18m
Sep 30 2022	CA$543k	CA$400k	-CA$19m
Jun 30 2022	n/a	n/a	-CA$13m
Mar 31 2022	n/a	n/a	-CA$9m
Dec 31 2021	n/a	n/a	-CA$10m
Sep 30 2021	CA$265k	CA$265k	-CA$11m
Jun 30 2021	n/a	n/a	-CA$11m
Mar 31 2021	n/a	n/a	-CA$12m
Dec 31 2020	n/a	n/a	-CA$10m
Sep 30 2020	CA$265k	CA$265k	-CA$9m
Jun 30 2020	n/a	n/a	-CA$9m
Mar 31 2020	n/a	n/a	-CA$9m
Dec 31 2019	n/a	n/a	-CA$8m
Sep 30 2019	CA$348k	CA$300k	-CA$8m
Jun 30 2019	n/a	n/a	-CA$7m
Mar 31 2019	n/a	n/a	-CA$7m
Dec 31 2018	n/a	n/a	-CA$7m
Sep 30 2018	CA$330k	CA$300k	-CA$7m
Jun 30 2018	n/a	n/a	-CA$7m
Mar 31 2018	n/a	n/a	-CA$7m
Dec 31 2017	n/a	n/a	-CA$6m
Sep 30 2017	CA$300k	CA$300k	-CA$6m
Jun 30 2017	n/a	n/a	-CA$6m
Mar 31 2017	n/a	n/a	-CA$5m
Dec 31 2016	n/a	n/a	-CA$5m
Sep 30 2016	CA$312k	CA$312k	-CA$5m

보상 대 시장: Andrew 의 총 보상 ($USD 399.88K )은 Canadian 시장( $USD 175.07K ).

보상과 수익: 회사가 수익성이 없는 동안 Andrew 의 보상이 증가했습니다.

CEO

Andrew Morris (57 yo)

2yrs

테뉴어

CA$543,040

보상

Mr. Andrew Morris is Chief Executive Officer of SQI Diagnostics Inc. from September 11, 2021 and Advisor to the board since June 05, 2023 and served as Director until June 05, 2023. He joined the SQI Diagn...

리더십 팀

이름	위치	테뉴어	보상	소유권
Andrew Morris	Advisor to the Board & CEO	2yrs	CA$543.04k	0.092% CA$ 5.6k
Morlan Reddock	CFO & VP of Administration	3.5yrs	CA$200.00k	데이터 없음
Eric Brouwer	Chief Scientific Officer & Advisor to the Board	5.9yrs	CA$350.00k	0.0049% CA$ 299.9
Peter Lea	Founder	24.7yrs	데이터 없음	데이터 없음
Tim McGough	Chief Commercial Officer	less than a year	데이터 없음	데이터 없음

3.5yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 관리: SQD 의 관리팀은 경험 ( 3.5 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Wilmot Matthews	Independent Director	8.4yrs	데이터 없음	23.03% CA$ 1.4m
Clive Beddoe	Independent Chairman of the Board	8.4yrs	데이터 없음	0.010% CA$ 612.6
Gerald Connor	Independent Director	8.4yrs	데이터 없음	24.5% CA$ 1.5m
Yehuda Shoenfeld	Chairman of Scientific Advisory Board	13.7yrs	데이터 없음	데이터 없음
Claude Ricks	Independent Director	16.3yrs	CA$4.00k	0.49% CA$ 29.9k
Eric Zwisler	Independent Director	5.3yrs	데이터 없음	데이터 없음

8.4yrs

평균 재임 기간

75.5yo

평균 연령

경험이 풍부한 이사회: SQD 의 이사회는 경험(평균 재직 기간 8.4 년)으로 간주됩니다.

SQI Diagnostics 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Clive J. Beddoe Announces Resignation as Director of SQI Diagnostics Inc

SQI Diagnostics Inc. Announces Executive Changes

SQI Diagnostics Inc., Annual General Meeting, Jun 30, 2023

Insufficient new directors

SQI Diagnostics Inc., Annual General Meeting, Apr 05, 2023

Independent Director recently sold CA$56k worth of stock

Recent updates

SQI Diagnostics Inc. Listing to Transfer to NEX Effective Feb. 20

Clive J. Beddoe Announces Resignation as Director of SQI Diagnostics Inc

SQI Diagnostics Expects its Common Shares to Continue to be Halted from Trading on Exchange and Ultimately Suspended and Delisted Following Completion of the Filing

SQI Diagnostics Inc. Announces Executive Changes

SQI Diagnostics Inc., Annual General Meeting, Jun 30, 2023

Second quarter 2023 earnings released: CA$0.009 loss per share (vs CA$0.007 loss in 2Q 2022)

Insufficient new directors

First quarter 2023 earnings released: CA$0.008 loss per share (vs CA$0.009 loss in 1Q 2022)

SQI Diagnostics Inc., Annual General Meeting, Apr 05, 2023

Full year 2022 earnings released: CA$0.048 loss per share (vs CA$0.031 loss in FY 2021)

SQI Installs Two Rali-Dx Systems in Toronto Hospitals to Fight the Growing Respiratory Health Crisis in Emergency Departments

SQI Diagnostics Inc. announced that it expects to receive CAD 1 million in funding

SQI Diagnostics Inc. announced that it expects to receive CAD 2 million in funding from Federal Economic Development Agency for Southern Ontario

SQI Diagnostics Announces Health Canada Approval of RALI-Dx Severity Triage Test

Third quarter 2022 earnings released: CA$0.012 loss per share (vs CA$0.002 loss in 3Q 2021)

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

SQI Diagnostics (CVE:SQD) Has Debt But No Earnings; Should You Worry?

New York State Approves SQI Diagnostics' Exact Covid-19 Antibody Assay

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

SQI Diagnostics Systems Inc. signed a definitive agreement to acquire all of the assets underlying Precision Biomonitoring Inc businesses from Precision Biomonitoring Inc. for CAD 6.825 million

SQI Diagnostics Inc. announced that it expects to receive CAD 6 million in funding

Third quarter 2021 earnings released: CA$0.002 loss per share (vs CA$0.005 loss in 3Q 2020)

Is SQI Diagnostics (CVE:SQD) Weighed On By Its Debt Load?

FDA Stops Emergency Use Authorization Review of SQI Diagnostics Inc. RALI-Dx IL-6 Severity Triage Test for Covid-19 Patients

CEO & Director Robert Chioini has left the company

Second quarter 2021 earnings released: CA$0.011 loss per share (vs CA$0.009 loss in 2Q 2020)

Health Check: How Prudently Does SQI Diagnostics (CVE:SQD) Use Debt?

Independent Director recently sold CA$56k worth of stock

Are Insiders Buying SQI Diagnostics Inc. (CVE:SQD) Stock?

First quarter 2021 earnings released: CA$0.012 loss per share (vs CA$0.009 loss in 1Q 2020)

Director exercised options to buy CA$705k worth of stock.

Director recently bought CA$660k worth of stock

New 90-day high: CA$0.40

SQI Diagnostics Inc., Annual General Meeting, Mar 31, 2021

Full year 2020 earnings released: CA$0.032 loss per share (vs CA$0.045 loss in FY 2019)

Is SQI Diagnostics Inc. (CVE:SQD) Popular Amongst Insiders?

SQI Diagnostics Announces Patient Enrollment Begins for its COVID-19 HOME Antibody Test Clinical Study

New 90-day high: CA$0.28

Independent Director exercised options to buy CA$1.7m worth of stock.

If You Had Bought SQI Diagnostics (CVE:SQD) Stock A Year Ago, You Could Pocket A 246% Gain Today

Is SQI Diagnostics (CVE:SQD) Using Debt Sensibly?

Sqi Diagnostics Inc. Updates Clinical Progress on Novel Covid-19 Tests Under Development for U.S. Fda Regulatory Submission

Third quarter earnings released

SQI Diagnostics Inc. Announces Executive Changes

New 90-day high - CA$0.21

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령